Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Change in Receivables (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Change in Receivables for 5 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables fell 372.47% year-over-year to -$1.2 million, compared with a TTM value of -$570246.0 through Sep 2025, down 131.97%, and an annual FY2024 reading of $601197.0, changed N/A over the prior year.
  • Change in Receivables was -$1.2 million for Q3 2025 at Kiora Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.2 million in Q2 2024 and bottomed at -$1.2 million in Q3 2025.